Please assess the completion status of the following clinical trial:

Trial Title: Rainbow Extension Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent from parent(s) or legal guardian(s), in compliance with local requirements~* The patient successfully completed the core study H2301, as defined by providing assessments at the Visit 112 (the last scheduled visit in the core study) or, if appropriate, at the last of the additional assessment visits as per protocol in H2301, whichever was latest~* The patient received study treatment in both eyes at baseline of study H2301~Exclusion Criteria:~* Patient had a medical condition or personal circumstance which precluded study participation or compliance with study procedures, as assessed by the Investigator~* Patient had been discontinued from the core study H2301 at any time

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.2 mg (Type: EXPERIMENTAL): 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
- Ranibizumab 0.1 mg (Type: EXPERIMENTAL): 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
- Laser therapy (Type: NO_INTERVENTION): Laser therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).